Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/51—Nanocapsules; Nanoparticles
  • A61K9/5107—Excipients; Inactive ingredients
  • A61K9/5115—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
  • A61N1/00—Electrotherapy; Circuits therefor
  • A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
  • A61N1/403—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia
  • A61N1/406—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia using implantable thermoseeds or injected particles for localized hyperthermia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
  • A61N2/00—Magnetotherapy
  • A61N2/004—Magnetotherapy specially adapted for a specific therapy
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents

Definitions

• the present invention pertains to the field of physical sciences. More especially, this invention relates to a system comprising nanoparticles and means to remotely apply a gradient of magnetic field on a tumor region.
• nanoparticles are injected intravenously in a subject having a tumor. Nanoparticles are injected and after migration, are located at the tumor region.
• This invention proposes a new medical system and method for the treatment of tumors, implementing an injection device comprising injectable magnetizable nanoparticles and a magnetic field gradient for generating a constraint field onto tumor surroundings, and optionally comprising magnets.
• the method of this invention involves the injection, in a subject in need thereof, of a number of magnetizable nanoparticles and the application of an external gradient of magnetic field in the tumor region where the nanoparticles are retained.
• the Applicant observed that, when the nanoparticles are injected intravenously, they are retained by the neoangiogenic network. It was observed that the randomized distribution of the injected nanoparticles in the neoangiogenic network surrounding the tumor surprisingly formed some kind of a hollow and discontinuous sphere. The tumor is thus located within said sphere.
• This configuration of injected nanoparticles in the neoangiogenic network surrounding the tumor creates conditions such that, when a gradient of magnetic field is applied onto the tumor region, a consequence of this application is the generation of a constraint field, and further of a constraint which is applied on the cells; this constraint leads to a change of the phenotype of the tumor cell to a normal or partially normal cell phenotype.
• this physical and/or mechanical constraint allows reducing the volume of a tumor and acts on the two histological surfaces of the tumor exposed to the external gradient of magnetic field.
• the biological effect is obtained by the physical and/or mechanical constraint applied on the tumor cells, said constraint resulting from the constraint field, itself resulting from the application of the gradient of magnetic field onto nanoparticles distributed in the neoangiogenic network surrounding the tumor.
• the invention relates to a medical system comprising (1) injectable magnetizable nanoparticles and means for injecting the same, and (2) means for applying a physical and/or mechanical constraint to a tumor associated to a neoangiogenic network where, after having been injected, the particles are retained, said means for applying a physical and/or mechanical constraint being a generator releasing a gradient of magnetic field; and
• the system is neither a cell construct nor an implant
• the system is not used for treating a tumor by pharmaceutical means such as drug targeting or thermotherapy;
• the particles are not used such as drug carrier or as imaging agent.
• this invention also relates to a method of treatment which is performed via the constraint applied on the cells; this constraint is a mechanical constraint. In one embodiment, this invention relates to a method of treatment which is performed via the constraint applied on the cells; this constraint is a contact-free constraint.
• the original approach of this invention shows that the mechanical constraint results from the force applied locally by the nanoparticles situated within the tumor region. The gradient of magnetic field directs the constraint field to the interior of the sphere, i.e. to the tumor cells. In the present invention, no movement of the particles is observed.
• the invention relates to a method for treating tumors by physical and/or mechanical means.
• the method of the invention further comprises a pharmaceutical agent. In one embodiment, the method of the invention does not comprise a pharmaceutical agent. In one embodiment, the method of the invention is not a pharmaceutical method.
• “About” refers preceding a figure means plus or less 10% of the value of said figure.
• “Phenotype” refers to the observable properties (structural and functional) of a living organism. In cancerology, the cell or tissue phenotype of a malignant tumor is observable properties which are disturbed, with comparison to the corresponding normal cell or tissue. For cell phenotype, said observable properties may be, none limitatively, growth, cell division, apoptosis, cell death, migration ability etc.
• Neoangiogenic network refers to the new vessels developing in the proximal area of the tumor. Proangiogenic molecules released from tumor cells are able to induce new vessel formation.
• a gradient is a vector indicating the variation or change, in space, of a physical quantity.
• a gradient of magnetic field is the rate of change of the strength of the field over distance.
• Magnetic field gradients are the forces used in quantum physics that exert a translational force on both a stationary and moving magnetizable particles. This is in contrast to a uniform magnetic field such as from a bipolar magnet which exerts zero force on magnetizable particles. The force/gradient relationship is represented by the formula
• F VP wherein F is the force, V is the gradient as a vector quantity and P is the magnetic potential.
• the gradient is measured in T/mm.
• Constraint field is a field applying a mechanical force.
• Constraint refers to a force divided by a surface, therefore homogeneous to a pressure and measured in Pascal (Pa) ; the state of stress or internal forces involved in different parts of the solid is defined by a stress tensor (Cauchy, 1822). These efforts are defined at each point of the solid and referred to as stress field or more generally tensor field. In physics of continuous medium, a field is, for each point of space-time, the value of a physical quantity. This quantity may be scalar (pressure) vector (magnetic field) or tensor.
• Malignant tumor refers to a cancerous tumor.
• Nanoparticle refers to nanospheres having a spherical shape, and a diameter ranging from 0.1 to 1000 nanometers. According to this invention, the nanoparticles are not hollow spheres, but solid spheres.
• Particle refers to magnetic beads under the form of unitary nanoparticles or of multitude of nanoparticles; said particle having a diameter ranging from 0.1 to 1000 nanometers; preferably the diameter is higher than 100 nm.
• “Stroma” refers to the tissue which forms the structure of an organ.
• Tumor region refers to a tumor; the extracellular matrix and/or the stroma; and the peripheric network of neovessels (the neoangiogenic network) surrounding the tumor.
• tissue refers to a consistent assembly of cells presenting the same phenotype.
• Figure 1 illustrates the general principle of the invention on a tumor.
• Figure 2 is a scheme showing a nude mouse 10 grafted subcutaneously 14 with a mixture of ferric nanoparticles 1 and MDA MB 231 (origin: human breast cancer) cells.
• Figure 3 illustrates the individual growth curves of the grafted tumors from DO to D80. Figure 3 also shows the limitation of the growth of the cancer cells after experimentation, with comparison to control.
• Figure 4 shows the proof of concept, in photo 4A and scheme 4B.
• Figure 5 is a scheme showing the positioning of two magnets on both sides of the tumor of a mouse.
• Figure 6 shows the comparison of the tumor volume for all mice between the treated group (Gl') to the three controls groups (G2'; G3' or G4').
• Figure 7 shows the comparison of the histological surfaces for all mice of the West side (Fig.7 A) or the East side (Fig.7B) of the tumor between the treated group (GT) to the three controls groups (G2'; G3' or G4').
• Figure 8 shows the evolution of the average in vivo tumor volume for the treated group (Gl') versus the control groups (G2'; G3' or G4').
• This invention relates to a medical system comprising (i) an injection device comprising injectable magnetizable nanoparticles 1 and means for injecting the same, and (ii) means for applying a physical and/or mechanical constraint to a tumor associated to a neoangiogenic network 7 where, after having been injected, the particles 1 are retained.
• a neoangiogenic network new blood vessels developing in the proximal area of the tumor while the stroma refers to the tissue which forms the structure of an organ.
• the stroma does not represent a vascularization network.
• the stroma is not a neoangiogenic network. Consequently, the present invention relates to a medical system for treating by physical and/or mechanical means tumor cells, wherein said means comprise magnetic particles specifically retained in the neoangiogenic network.
• the medical system is not a cell construct or an implant.
• the medical system does not comprise a pharmaceutical agent for treating the tumor; in particular the nanoparticles are not used as drug carriers.
• the medical system is not for use as an imaging or a contrast system.
• the tumor is associated with an angiogenic network 7. In another embodiment, the tumor is a locally advanced tumor. In one embodiment, the tumor is a malignant epithelial tumor. In one embodiment, the malignant tumor is pancreas cancer. In one embodiment, the malignant tumor is liver cancer. In another embodiment, the malignant tumor is breast cancer. In one embodiment, the tumor is within an animal or a human body. Means for applying a mechanical and/or physical constraint
• the means for applying a mechanical and/or physical constraint is a generator releasing a gradient of magnetic field 2.
• the magnetic field generator is controlled to produce a gradient of magnetic field 2.
• the generator comprises an electromagnet 9.
• the generator is a coil, preferably a moving coil, more preferably a Helmotz coil in a tumble configuration.
• the means for applying a mechanical and/or physical constraint further comprise at least one magnet, permanent magnet and/or electromagnet; preferably said means further comprise more than one external magnet, permanent magnet and/or electromagnet; more preferably more than one external magnet, permanent magnet and/or electromagnet are localized at various preferably opposite sides of the tumor.
• means for applying a mechanical and/or physical constraint are located outside the tumor, preferably located outside the body of the subject.
• the means are moving, preferably turning around the tumor region.
• the means are located at a distance at the tumor ranging from 0.1 to 100 mm; preferably 1 to 10 mm.
• the magnetic field is a variable or constant external field, having a frequency varying or ranging from 0.1Hz to 1 TeraHz, preferably from 1 Hz to 1 MHz, more preferably from 10 Hz to 500 kHz. In one embodiment, the magnetic field ranges from 0.1 ⁇ to 50 T, preferably from 0.01 mT to 5 T, more preferably from 0.1 mT to 700 mT.
• the magnetic field is moving, preferably turning around the tumor region.
• the magnetic field is not an alternative field. In one embodiment, the magnetic field is not an alternative current electric field.
• the gradient of magnetic field 2 varies in intensity, frequency and/or in direction.
• the gradient of magnetic field 2 is applied in a way such that the constraint on the tumor varies in intensity, direction and frequency.
• One skilled in the art shall modify the intensity, frequency and/or in direction of the gradient of magnetic field, depending on the location of the tumor and its size and possibly on other biological data.
• the gradient of magnetic field 2 ranges from 0.001 to 10 T/cm, preferably from 0.01 to 1 T/cm, more preferably from 0.1 to 0.5 T/cm; even more preferably around 0.4 T/cm.
• the frequencies of the gradient of field 2 may be varied to search and reach a constraint field having the resonance frequency, or harmonics thereof, of the cytoskeleton and/or of cells walls and/or of the surrounding soft and/or hard tissues.
• the frequency of the gradient of field may be adapted so that the constraint field triggers the resonance frequency of the continuous assembly formed by the tumor cells components in the tumor.
• the system comprises means to vary the direction of the magnetic field or the direction of the generator, in order to direct the field.
• the particles or nanoparticles 1 comprises, are composed of or consists of any magnetizable material, preferably, iron oxide or manganese, more preferably magnetite (Fe304), maghemite ([gamma]-Fe203) or ferumoxides, i.e. a dextran-coated colloidal iron oxide, or mixtures thereof.
• magnetizable material preferably, iron oxide or manganese, more preferably magnetite (Fe304), maghemite ([gamma]-Fe203) or ferumoxides, i.e. a dextran-coated colloidal iron oxide, or mixtures thereof.
• particle it is understood in the present invention, one unitary particle or an assembly of nanoparticles.
• the particles or nanoparticles 1 have a size or a hydrodynamic volume such that they cannot be uptaken by the tumor cells.
• the particles or nanoparticles 1 have a size or a hydrodynamic volume such that they are retained by the neoangiogenic network 7 surrounding the tumor and remain at the periphery of the tumor without entering into the tumor or the tumor cells.
• the particles or nanoparticles 1 have a mean diameter ranging from 30 to 1000 nm, preferably 40 to 800 nm, more preferably 60 to 300 nm.
• the particles or nanoparticles have a mean diameter higher than 100 nm in order to avoid capture by the cell tumors and/or organs; preferably about 200 nm.
• the quantity of the particles or nanoparticles 1 loaded in the body is ranging from 0.1 mg to 1000 mg, preferably 1 to 10, more preferably about 5 mg.
• the particles or nanoparticles 1 are not coated.
• the particles or nanoparticles 1 are coated with a non- pharmaceutical composition, preferably said nanoparticles 1 are coated with a hydrophilic coating, more preferably dextran. In another embodiment, the particles or nanoparticles 1 are coated with a pharmaceutical composition.
• the particles or nanoparticles 1 are coated with at least one biochemical agent; preferably a peptide; more preferably, arginylglycylaspartic acid (RGD).
• the particles or nanoparticles 1 may be helped in their migration towards the tumor region, for example through specific coatings applied onto the nanoparticles 1 prior to injection.
• the particles or nanoparticles 1 are formulated within a suspension, wherein the particles or nanoparticles 1 are suspended in a colloidal or non-colloidal vehicle.
• the injection device encompassed in this invention comprises a suspension comprising the magnetizable particles or nanoparticles 1 as described above.
• the particles or nanoparticles 1 are formulated within an emulsion, wherein the particles or nanoparticles 1 are in an emulsion.
• the injection device encompassed in this invention comprises an emulsion comprising the magnetizable particles or nanoparticles 1 as described above.
• This invention also relates to method for treating tumors by physical and/or mechanical means, especially tumors associated with a neoangiogenic network 7, comprising the steps of:
• compositions preferably a suspension or an emulsion, containing the particles or nanoparticles 1, preferably magnetizable particles or nanoparticles, more preferably iron-based or ferric particles or nanoparticles having a mean diameter ranging from 30 to 1000 nm, preferably 40 to 800 nm, more preferably 60 to 300 nm;
• the nanoparticles 1 used in the method of the invention are as described above. According to the invention, at least 25-60% of the injected particles or nanoparticles 1 are retained in the tumor neoangiogenic network 7. Without willing to be linked by a theory, the Applicant tends to believe that the particles or nanoparticles 1 of the system of the invention, when injected, benefit from the well-known Enhanced Permeability and Retention (EPR) effect, and preferably mainly from the enhanced retention effect, with regard to the neoangiogenic network 7.
• EPR effect is the property by which certain sizes of particles or nanoparticles 1 tend to accumulate in tumor regions much more than they do in normal tissues.
• the EPR effect helps directing the particles or nanoparticles 1 to the tumor region. However, due to the nature and the size of the particles 1 of the invention, they may not enter or contact the tumor cells, and get retained in the neoangiogenic network 7 surrounding the tumor.
• the EPR ratio of the particles or nanoparticles 1 of the invention i.e. the amount of injected particles or nanoparticles 1 reaching the neoangiogenic network 7 ranges from 25% to 60%. In another embodiment, the EPR ratio ranges from 30% to 40% of the injected particles 1.
• the EPR ratio may vary, depending on the size of the particles or nanoparticles 1 and/or the location of the tumor region and/or the histological nature of the tumor.
• the particles or nanoparticles 1 are retained by the neoangiogenic network 7 surrounding the tumor; in one embodiment, the distribution of the particles or nanoparticles 1 forms a hollow and discontinuous sphere.
• the particles or nanoparticles are not retained by or in the stroma.
• the particles or nanoparticles 1 may not contact the tumor cells.
• the distance between a tumor cell and the particles or nanoparticle 1 is at least 1 (one) micron, preferably 5 to 100 ⁇ .
• the amount of injected particles or nanoparticles 1 ranges from 100 ⁇ g to lOg, preferably from 500 ⁇ g to 2g.
• the means for applying a contact-free constraint is an external generator as described above.
• external is meant that the generation of the gradient of magnetic field 2 is located outside the tumor, preferably located outside the body of the subject.
• the gradient of magnetic field 2 is applied for a period of time, ranging from 1 minute to 48 hours, preferably 15 minutes to 5 hours, this period of time being repeated over several weeks.
• the subject is an animal, including a human.
• the subject may be a male or a female. This subject encompasses, within his/her/its body a tumor associated with an angiogenic network 7.
• the tumor is a locally advanced tumor.
• the tumor is a malignant epithelial tumor.
• the malignant tumor is pancreas cancer tumor.
• the malignant tumor is breast cancer tumor.
• This invention also relates to a method for modifying the cancerous phenotype of cancer cells to normal cells in a target region, the method comprising the steps of: injecting a composition, preferably a suspension or an emulsion, containing the particles or nanoparticles 1 as described above, such that the particles or nanoparticles 1 are retained by the neoangiogenic network 7 surrounding the tumor; preferably, the injection is performed intravenously and the particles or nanoparticles 1 migrate spontaneously to the neoangiogenic network 7 of the tumor;
• this means comprising or consisting of a gradient of magnetic field 2 applied on the particles or nanoparticles 1, in vivo, from an outside source of gradient of magnetic field 2.
• the invention also relates to a method for reducing the volume and the surfaces of tumor cells in a target region, the method comprising the steps of:
• a composition preferably a suspension or an emulsion, containing the particles or nanoparticles 1 as described above, such that the particles or nanoparticles 1 are retained by the neoangiogenic network 7 surrounding the tumor; preferably, the injection is performed intravenously and the particles or nanoparticles 1 migrate spontaneously to the neoangiogenic network 7 of the tumor;
• a contact-free constraint such as for example a contact-free pressure
• this means comprising or consisting of a gradient of magnetic field 2 applied on the particles or nanoparticles 1, in vivo, from an outside source of gradient of magnetic field 2.
• Figure 1 illustrates a tumor encompassing, in its peripheric neoangiogenic networks 7, the nanoparticles 1 as described herein.
• the nude mouse 10 is grafted subcutaneously 14 with a mixture of ferric nanoparticles 1 and MDA MB 231 (origin: human breast cancer) cells.
• the mouse 10 is placed in the gap of two magnets 9, as shown on Figure 2; in the example of Figure 2, one magnet is as close as possible to the tumor, whereas the opposite magnet is at a distance d of the periphery of the tumor, this distance d corresponding to the diameter of the tumor.
• mice The aims of the study were to analyze 10 human tumors (MDA-MB-231, breast cancer cell line), subcutaneously grafted in mice, and investigate:
• mice 10 Five mice 10 were subcutaneously grafted between skin (West side) 16 and muscle (East side) 15 with human cells of cell line MDA MB 231 (two xenografts per mouse). At the end of the study, all tumors were collected, fixed in 4% formalin and included in paraffin. One of the two xenografts from each mouse 10 was processed for evaluating histopathological features of the tumors (HES staining). Both xenografts samples from each mouse were processed for evaluating tumor cells iron accumulation (Perls special stain). In this study, the ten evaluated MDA-MB-231 xenografts presented comparable histological features, and appeared as undifferentiated carcinomas. Necrotic areas 13 were seen in the central parts of every tumor.
• Iron deposits were located in the peri-tumoral areas. They appeared as brown granular deposits on HES stained slides and as dark blue granular deposits in Perls stained slides. No iron deposits were identified in tumor cells, in any tumor of any group.
• MDA-MB-231 xenografts presented comparable histological features, and appeared as undifferentiated carcinomas, without glandular differentiation. These tumors were densely cellular, quite well demarcated and roughly nodular, with infiltrative growth in adjacent subcutaneous tissues, in particular nerves.
• inflammatory cells were found in peri-tumoral fibrous stroma, as well as in adjacent tissues in smaller amounts (adipose tissue, skeletal muscle, skin). Those cells mostly consisted in pigment-laden macrophages, with some small lymphocytes and occasional granulocytes. Low numbers of similar inflammatory cells, including pigment-laden macrophages, were also observed in the scant intra-tumoral stroma. Those cells were mainly observed in peripheral parts of the tumor, probably spreading from the peri-tumoral stroma. Pigment-laden macrophages were medium to large-sized cells, and displayed a large cytoplasm which contained large amounts of brown granular pigment, often overlying and hiding round nuclei. Such pigment was occasionally found in the peri-tumoral and intra-tumoral stroma as granular pigment debris.
• Perls' acid ferrocyanide reaction revealed iron compounds through dark blue labeling. For each tumor, three consecutive sections were evaluated. All three of those sections displayed comparable features. No blue-stained iron deposits were identified in tumor cells, in any tumor of any group.
• the particles 1 were distributed around the tumor and surprisingly formed a hollow and discontinuous sphere.
• the conditions for applying a constraint on the tumor seem to be gathered.
• Example 2 Ability to modify the cancerous phenotype by a constraint in animals
• the aim of the study is to investigate the antitumor efficiency of nanoparticles activated by a magnetic field in the model of subcutaneous MDA-MB-231 human breast tumor bearing mice.
• Nanoparticles are administered with tumor cells (at the time of tumor cells injection) to Balb/c Nude mice.
• the injection volume for the Nanoparticles is 300
• mice When submitted to the magnetic field using magnet-bearing devices, animals are anaesthetized (with isoflurane) and body temperature of mice is maintained within physiological levels by infrared lamps.
• mice 10 were placed in the gap of two magnets 9 in repulsive mode (see Figure 2).
• a gradient of magnetic field 2 is then applied.
• the gradient applied is about 0.4 Tesla/cm at a depth of 3mm.
• DA-MB-231 tumor cells resuspended in a volume of 0.3 mL RPMI 1640 medium containing 5 mg of nanoparticles or no nanoparticles are subcutaneously inoculated in the flanks of 45 female SWISS Nude mice, irradiated 24-72 hours before with a ⁇ -source (whole body irradiation, 2 Gy, 60Co, BioMEP Sari, Breteniere, France).
• Tumors cells without the nanoparticles are injected in the left flank of all 45 mice. Tumors cells with the nanoparticles are injected in the right flank of all 45 mice. The day of tumor cells injection is considered as the day 0 (DO).
• Tumor volume 1 ⁇ 2 X length Xwidth
• mice When the mean tumor volume reaches approximately 100-200 mm , 36 tumor bearing female Balb/c Nude mice are randomized into 3 groups (one group of 8 mice and two groups of 14 mice) according to their individual tumor volumes.
• the treatment schedule was chosen as follows:
• Group 1 The tumor on the left flank (containing no nanoparticles) of the eight (8) mice is submitted to the magnetic field once a day for two consecutive hours for 21 consecutive days.
• Group 3 The tumor on the right flank (containing nanoparticles) of the fourteen (14) mice is submitted to the magnetic field once a day for two consecutive hours for 21 consecutive days.
• Treatments i.e. submission to the magnetic field
• the table 1 summarizes the treatment schedule:
• Group with nanoparticles 1, without gradient field 2 group 1 right tumor and group 2 right tumor.
• Group without nanoparticles 1, with field gradient 2 group 1 left tumor.
• Group without nanoparticles 1, without field gradient 2 group 2 left tumor and group 3 left tumor.
• Tumors are resected and cut into two pieces. The two pieces will be fixed in 10% neutral buffered formalin. Results
• the treated group (with nanoparticles 1 and with gradient field 2, i.e. Right Tumor G3) was compared with three control groups: There were two statistically significant changes (p ⁇ 0.05):
• the overall tumor growth 11/12 is lower in the treated group compared to the three control groups, see Figure 3.
• the more detailed analysis of treated tumors was used to compare the West side and the East side: increase of the thickness of the active part of the tumor on the West side 11 and decrease of the active part of the tumor on the East side 12 in the treated tumors (with nanoparticles an gradient of magnetic field) when compared to the control groups.
• the tumoral volume is much lower in the group
• Example 3 Ability to modify the volume and surfaces of a tumor by a physical and/or mechanical constraint in animals
• the aim of the study is to investigate the reduction of the tumor volume and the surfaces due to nanoparticles activated by a gradient of magnetic field in the model of subcutaneous MDA-MB-231 human breast tumor bearing mice.
• mice were subcutaneously grafted between skin and muscle with human cells of cell line MDA MB 231. When tumors reached approximately one centimeter tumors in the treated group, the mice were placed in the air-gap of two magnets in a repulsive mode with a particular geometry as shown Figure 2.
• mice having a one-centimeter- sized tumor were distributed in 4 groups:
• control group Group wherein no particle is injected into mice and no gradient of magnetic field is used.
• the day of tumor cells injection is considered as the day 0 (DO).
• the volume is calculated in mm .
• the treated group (Gl') was compared to the whole untreated group comprising G2', G3' and G4'.
• the table 2 below and Figure 8 summarize the results taken after 59 days for all the subcutaneously grafted mice.
• this example shows that the medical system comprising injectable nanoparticles and a gradient of magnetic field is the best method to reduce a tumor volume by mechanical and/or physical means.
• the results show that the surfaces of the treated group are significantly different to untreated groups (mixed up).
• the surfaces on group treated are lower than on group untreated (estimate of difference is equal to -0.344 log for West side and to - 0.485 for East side).

Landscapes

• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Biomedical Technology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Radiology & Medical Imaging (AREA)
• Physics & Mathematics (AREA)
• Inorganic Chemistry (AREA)
• Nanotechnology (AREA)
• Optics & Photonics (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Magnetic Treatment Devices (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (1)

Family

ID=48793929

Family Applications (1)

Country Status (4)

Families Citing this family (4)

Citations (3)

Family Cites Families (7)

• 2013
  • 2013-07-12 EP EP13176364.1A patent/EP2823858A1/en not_active Withdrawn
• 2014
  • 2014-07-11 EP EP14738529.8A patent/EP3019236A1/en active Pending
  • 2014-07-11 US US14/904,580 patent/US10449160B2/en not_active Expired - Fee Related
  • 2014-07-11 JP JP2016524845A patent/JP6534660B2/ja not_active Expired - Fee Related
  • 2014-07-11 WO PCT/EP2014/064995 patent/WO2015004285A1/en not_active Ceased

Patent Citations (3)

Also Published As

Similar Documents

Legal Events